Klin Farmakol Farm. 2017;31(1):37-39 | DOI: 10.36290/far.2017.030

Cilostazol in treating lower limb ischaemia

Dalibor Musil
I. interní klinika – kardiologická LF a FN Olomouc

Cilostazol is a vasodilator with antiplatelet and metabolic properties. In addition to physical activity, it is used in the treatment of
intermittent claudications, i. e. classic clinical signs of chronic limb ischaemia. Professional societies’ guidelines list it as the first
drug of choice. While the effect of cilostazol on claudications has been evaluated in a number of studies, its options for affecting
the individual cardiovascular and cerebrovascular risks still remain unappreciated.

Keywords: antiaggregation, thrombocytes, vasodilation, intermittent claudications, critical limb ischaemia, stroke prevention

Received: January 6, 2019; Accepted: January 14, 2019; Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Musil D. Cilostazol in treating lower limb ischaemia. Klin Farmakol Farm. 2017;31(1):37-39. doi: 10.36290/far.2017.030.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Karetová D, Bultas J. Cilostazol. Remedia 2014; 441-449.
    2. Rooke TW, Hirsch AT, Misra S, et al. 2011 ACC/AHA focused update of the Guidelines for the management of patients with peripheral artery disease (updating the 2005 guidelines). Circulation 2011; 124: 2020-2045. Go to original source... Go to PubMed...
    3. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33: S1-S70. Go to original source... Go to PubMed...
    4. Bedenis R, Stewart M, Cleanthis S, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2014 Oct 31; (10): CD003748. doi: 10.1002/14651858.CD003748.pub4. Go to original source... Go to PubMed...
    5. Gotoh F, Hideo T, Shunsaku H, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-157. Go to original source... Go to PubMed...
    6. Uschiyama S. Results of the Cilostazol Stroke Prevention Study II (CSPS II): a randomized controlled trial for the comparison of cilostazol and aspirin in stroke patients. Rinsho Shinkeigaku 2010; 50: 832-834. Go to original source... Go to PubMed...
    7. Prat C. Analysis of the cilostazol safety database. Am J Cardiol 2001; 87: 28D-33D. Go to original source... Go to PubMed...
    8. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523-530. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.